articleTop 1% cited

Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

The Journal of Urology · 2004 · Vol. 171(3) · pp. 1071–1076

Robert C. Flanigan✉(SWOG Cancer Research Network)G. Mickisch(SWOG Cancer Research Network)Richard Sylvester(SWOG Cancer Research Network)Cathy Tangen(SWOG Cancer Research Network)Hendrik Van Poppel(Loyola University Medical Center)E. David Crawford(SWOG Cancer Research Network)

View via DOI Publisher page

Abstract

Cytoreductive nephrectomy appears to improve significantly overall survival in patients with metastatic renal cancer treated with interferon immunotherapy independent of patient performance status, the site of metastases and the presence of measurable disease. Although it is highly statistically significant, the overall survival advantage is only 5.8 months for the entire group. These data emphasize the need to determine if this survival advantage can be further improved using more aggressive immunotherapy or other novel agents in the setting of cytoreductive nephrectomy.

Renal cell carcinoma treatment Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology StudiesMedicineNephrectomyRandomizationClinical endpointInternal medicineRandomized controlled trialAlpha interferonKidney cancerOncologyRenal cell carcinoma

MeSH terms

Interferon alpha-2AdultAgedAged, 80 and overAntineoplastic AgentsCombined Modality TherapyFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm MetastasisNephrectomyProspective StudiesRecombinant Proteins

Citations

871

FWCI

22.62

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

EAU Guidelines on Renal Cell Carcinoma: 2014 Update